Structure-kinetic relationship of carbapenem antibacterials permeating through E. coli OmpC porin

Proteins: Structure, Function and Bioinformatics

Volumn 82, Issue 11, 2014, Pages 2998-3012

  Tran, Que Tien ^a   Pearlstein, Robert A ^a   Williams, Sarah ^a   Reilly, John ^a   Krucker, Thomas ^a   Erdemli, Gül ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Antibiotics; Drug transport; Electrophysiology; Gram negative bacteria; Membrane proteins; Microbiology; Translocation kinetics

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BIAPENEM; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; ERYTHROMYCIN; ESCHERICHIA COLI PORIN; ESCHERICHIA COLI PROTEIN; IMIPENEM; MEROPENEM; NORFLOXACIN; PANIPENEM; PIPERACILLIN; POLYMYXIN; PORIN; RAZUPENEM; RIFAMPICIN; SOLVENT; TEBIPENEM PIVOXIL; TICARCILLIN; UNCLASSIFIED DRUG; VANCOMYCIN; WATER; ANTIINFECTIVE AGENT; LIPID BILAYER; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN C; PHOSPHOLIPID;

ARTICLE; BACTERIAL CELL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; KINETICS; NONHUMAN; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; LIPID BILAYER; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; CARBAPENEMS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; KINETICS; LIPID BILAYERS; MICROBIAL SENSITIVITY TESTS; PHOSPHOLIPIDS; PORINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937577985     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24659     Document Type: Article

References (60)

1. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Moller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011;365:709-717.
2. Livermore DM, British Soc A. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrobial Chemotherapy 2011;66:1941-1944.
3. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJV, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. Tackling antibiotic resistance. Nat Rev Microbiol 2011;9:894-896.
4. Page MGP, Kellenberger L. Stemming the tide? Advances in antibiotic discovery and development in the face of emerging resistance and financial constraint. Curr Opin Pharmacol 2012;12:519-521.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Dis 2007;6:29-40.
6. Hawkey PM, Livermore DM. Carbapenem antibiotics for serious infections. BMJ 2012;344.
7. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrobial Agents Chemotherapy 2011;55:4943-4960.
8. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-2545.
9. Goldraich NP, Manfroi A. Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. Pediatr Nephrol 2002;17:173-176.
10. Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrobial Chemotherapy 2011;66:2298-2307.
11. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, Cars O, Grp E-EW. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Update 2011;14:118-124.
12. Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008;6:893-903.
13. Nikaido H. Porins and specific diffusion channels in bacterial outer membranes. J Biol Chem 1994;269:3905-3908.
14. Basle A, Rummel G, Storici P, Rosenbusch JP, Schirmer T. Crystal structure of osmoporin OmpC from E. coli at 2.0 A. J Mol Biol 2006;362:933-942.
15. Low AS, MacKenzie FM, Gould IM, Booth IR. Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long-term antibiotic therapy. Mol Microbiol 2001;42:619-630.
16. Lou H, Chen M, Black SS, Bushell SR, Ceccarelli M, Mach T, Beis K, Low AS, Bamford VA, Booth IR, Bayley H, Naismith JH. Altered antibiotic transport in OmpC mutants isolated from a series of clinical strains of multi-drug resistant E. coli. PLoS ONE 2011;6:e25825.
17. Misra R, Benson SA. Isolation and characterization of OmpC porin mutants with altered pore properties. J Bacteriol 1988;170:528-533.
18. Liu N, Delcour AH. The spontaneous gating activity of OmpC porin is affected by mutations of a putative hydrogen bond network or of a salt bridge between the L3 loop and the barrel. Protein Eng 1998;11:797-802.
19. Llarrull LI, Testero SA, Fisher JF, Mobashery S. The future of the β-lactams. Curr Opin Microbiol 2010;13:551-557.
20. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-S172.
21. Fong JJ, Rosé L, Radigan EA. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria. Annals Pharmacotherapy 2012;46:347-352.
22. El-Gamal MI, Oh CH. Current status of carbapenem antibiotics. Curr Topics Med Chem 2010;10:1882-1897.
23. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010;300:371-379.
24. Adler M, Anjum M, Andersson DI, Sandegren L. Influence of acquired β-lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli. J Antimicrobial Chemotherapy 2013;68:51-59.
25. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, Saavedra JM, Perez-Vazquez M, Garcia-Cobos S, Martinez-Martinez L, Campos J. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrobial Agents 2008;32:534-537.
26. James CE, Mahendran KR, Molitor A, Bolla J-M, Bessonov AN, Winterhalter M, Pagès J-M. How β-lactam antibiotics enter bacteria: a dialogue with the porins. PLoS ONE 2009;4:e5453.
27. Mahendran KR, Kreir M, Weingart H, Fertig N, Winterhalter M. Permeation of antibiotics through Escherichia coli OmpF and OmpC porins: screening for influx on a single-molecule level. J Biomol Screen 2010;15:302-307.
28. Tran Q-T, Williams S, Farid R, Erdemli G, Pearlstein R. The translocation kinetics of antibiotics through porin OmpC: insights from structure-based solvation mapping using WaterMap. Proteins 2013;81:291-299.
29. Prilipov A, Phale PS, Van Gelder P, Rosenbusch JP, Koebnik R. Coupling site-directed mutagenesis with high-level expression: large scale production of mutant porins from E-coli. Fems Microbiol Lett 1998;163:65-72.
30. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrobial Chemotherapy 2001;48:5-16.
31. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protocols 2006;1:2856-2860.
32. Hajjar E, Mahendran KR, Kumar A, Bessonov A, Petrescu M, Weingart H, Ruggerone P, Winterhalter M, Ceccarelli M. Bridging timescales and length scales: from macroscopic flux to the molecular mechanism of antibiotic diffusion through porins. Biophys J 2010;98:569-577.
33. Mahendran KR, Hajjar E, Mach T, Lovelle M, Kumar A, Sousa I, Spiga E, Weingart H, Gameiro P, Winterhalter M, Ceccarelli M. Molecular basis of enrofloxacin translocation through OmpF, an outer membrane channel of Escherichia coli-when binding does not imply translocation. J Phys Chem B 2010;114:5170-5179.
34. Montal M, Mueller P. Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci USA 1972;69:3561-3566.
35. Bot CT, Prodan C. Quantifying the membrane potential during E. coli growth stages. Biophys Chem 2010;146(2-3):133-137.
36. Schwarz G, Danelon C, Winterhalter M. On translocation through a membrane channel via an internal binding site: kinetics and voltage dependence. Biophys J 2003;84:2990-2998.
37. Valko K, Du CM, Bevan CD, Reynolds DP, Abraham MH. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J Pharmaceutical Sci 2000;89:1085-1096.
38. Faller B. Artificial membrane assays to assess permeability. Current Drug Metabolism 2008;9:886-892.
39. Abel R, Young T, Farid R, Berne BJ, Friesner RA. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J Am Chem Soc 2008;130:2817-2831.
40. Young T, Abel R, Kim B, Berne BJ, Friesner RA. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Natl Acad Sci USA 2007;104:808-813.
41. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochimica Et Biophysica Acta-Proteins Proteomics 2009;1794:808-816.
42. Tran Q-T, Mahendran KR, Hajjar E, Ceccarelli M, Davin-Regli A, Winterhalter M, Weingart H, Pagès J-M. Implication of porins in β-lactam resistance of providencia stuartii. J Biol Chem 2010;285:32273-32281.
43. Knowles TJ, Scott-Tucker A, Overduin M, Henderson IR. Membrane protein architects: the role of the BAM complex in outer membrane protein assembly. Nat Rev Micro 2009;7:206-214.
44. Surrey T, Jahnig F. Refolding and oriented insertion of a membrane-protein into a lipid bilayer. Proc Natl Acad Sci USA 1992;89:7457-7461.
45. Kojima S, Nikaido H. Permeation rates of penicillins indicate that Escherichia coli porins function principally as nonspecific channels. Proc Natl Acad Sci USA 2013;110:E2629-E2634.
46. Ong S, Liu H, Pidgeon C. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatography A 1996;728(1-2):113-128.
47. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrobial Agents Chemotherapy 1994;38:1742-1752.
48. Danelon C, Nestorovich EM, Winterhalter M, Ceccarelli M, Bezrukov SM. Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys J 2006;90:1617-1627.
49. Liu YF, Yan JJ, Lei HY, Teng CH, Wang MC, Tseng CC, Wu JJ. Loss of outer membrane protein C in Escherichia coli contributes to both antibiotic resistance and escaping antibody-dependent bactericidal activity. Infection Immunity 2012;80:1815-1822.
50. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003;67:593-656.
51. Bajaj H, Tran Q-T, Mahendran KR, Nasrallah C, Colletier J-P, Davin-Regli A, Bolla J-M, Pagès J-M, Winterhalter M. Antibiotic uptake through membrane channels: role of providencia stuartii OmpPst1 porin in carbapenem resistance. Biochemistry 2012;51:10244-10249.
52. Page MGP, Heim J. New molecules from old classes: revisiting the development of beta-lactams. IDrugs 2009;12:561-565.
53. Tran CM, Tanaka K, Yamagishi Y, Goto T, Mikamo H, Watanabe K. In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrobial Agents Chemotherapy 2011;55:2398-2402.
54. Flarakos J, Ting LSL, Du Y, Stein DS, Reynolds CV, Patel M, Roy S, Mangold JB. Disposition and metabolism of [14C]PTZ601 in healthy volunteers. Xenobiotica 2012:1-10.
55. Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents Chemotherapy 2008;52:1510-1512.
56. Yamachika S, Sugihara C, Kamai Y, Yamashita M. Correlation between penicillin-binding protein 2 mutations and carbapenem resistance in Escherichia coli. J Med Microbiol 2013;62(Part 3):429-436.
57. Dougherty TJ, Kennedy K, Kessler RE, Pucci MJ. Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli. J Bacteriol 1996;178:6110-6115.
58. Ziervogel Brigitte K, Roux B. The binding of antibiotics in OmpF porin. Structure 2013;21:76-87.
59. Hajjar E, Bessonov A, Molitor A, Kumar A, Mahendran KR, Winterhalter M, Pagès J-M, Ruggerone P, Ceccarelli M. Toward screening for antibiotics with enhanced permeation properties through bacterial porins. Biochemistry 2010;49:6928-6935.
60. Fujimoto K, Takemoto K, Hatano K, Nakai T, Terashita S, Matsumoto M, Eriguchi Y, Eguchi K, Shimizudani T, Sato K, Kanazawa K, Sunagawa M, Ueda Y. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrobial Agents Chemotherapy 2013;57:697-707.